This kit detects mutations in the epidermal growth factor receptor (EGFR) gene. The product is highly specific and sensitive, covering a total of 29 mutation sites including drug-sensitive and drug-resistant. It is used to assist clinicians in screening non-small cell lung cancer patients who could benefit from targeted drugs such as Erizar (Gefitinib), Trocet (Erlotinib) and Kemena (Ectinib).

Features: easy to use, one-step method, 90-minute results; accurate results, highest sensitivity for 1% mutant allele; universally applicable, compatible with tissue and peripheral blood samples.

Applicable samples: fresh tissue, frozen tissue, paraffin-embedded tissue, serum, plasma, etc.

EGFR is a common driver gene in Asian non-small cell lung cancer (NSCLC) populations, with a mutation frequency of approximately 30% in NSCLC, 50% in lung adenocarcinoma, and 10% in squamous lung cancer. Currently, the EGFR gene has become an important biomarker for tyrosine kinase inhibition (TKIs) therapy in NSCLC patients.

Clinically, some patients with advanced lung cancer do not benefit from EGFR-TKI therapy due to the lack of sufficient tumor tissue or cytology specimens. In recent years, as a complement to tissue specimens, blood samples have demonstrated great potential for clinical application. Meanwhile, compared with tissue testing, plasma testing has the advantages of easy collection, non-invasive, and safe, which makes it easier to be accepted by the examinees.